Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 6 min read

What is Melanotan II?

Melanotan II is an unlicensed synthetic peptide analog in the melanocortin hormone family that acts primarily at melanocortin 1 receptors on melanocytes. This page summarises the research record, including animal-only an

peptides-pro Editorial

Melanotan II (also written MT-II) is an unlicensed synthetic peptide analog belonging to the melanocortin hormone family [1]. It is a cyclic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), and in the research literature it is described as a non-selective melanocortin receptor agonist. The evidence block for this page does not supply a sequence, molecular formula, or molecular weight for Melanotan II, so none are stated here. The compound is not approved as a medicine in any jurisdiction covered by the sources below, and its sale is described as illegal in the United Kingdom [3].

The work summarised on this page centres on the melanocortin receptor family, a group of five Class A G protein-coupled receptors (MC1R through MC5R) with roles that include pigmentation, steroidogenesis, and energy homeostasis [6]. Melanotan II acts primarily by activating melanocortin 1 receptors on melanocytes, stimulating eumelanin production and producing skin pigmentation independent of sun exposure [1].

Research Studies

Melanotan II and oral mucosal pigmentation in a human case report

A case report followed a patient for three months after self-administered Melanotan II injections given over a period of 64 days, with the stated goal of achieving a deeper tanning effect [1]. On initial intraoral examination, brown pigmentation was observed. The report frames the finding within the compound's known mechanism: activation of melanocortin 1 receptors on melanocytes drives eumelanin production, and pigmentation can therefore appear in tissues beyond the skin, including the oral mucosa [1]. The authors note that despite its popularity, particularly through promotion on social media, Melanotan II remains unregulated and its use is associated with a range of potential adverse effects [1]. This is a single-patient observational report; it does not establish incidence or causation, and it is not a controlled study.

Melanotan II and repigmentation in stable nonsegmental vitiligo

A registered randomized Phase 2 clinical trial evaluated investigational Melanotan II as an adjunct to standard narrowband UVB (NB-UVB) phototherapy for repigmentation in adults with stable nonsegmental vitiligo [2]. The record describes the design as interventional and randomized, with the compound used alongside phototherapy rather than as monotherapy. No results are reported in the evidence block, so no efficacy or safety conclusions can be drawn here. The trial is the only controlled human study design represented in the sources for this page.

Melanotan II and oral mucosal malignant melanoma in a human case report

A published case report describes a 22-year-old female who developed a mass in the anterior maxilla after using a Melanotan II nasal spray containing a synthetic analogue of melanocyte-stimulating hormone [3]. The patient had used the spray for tanning purposes. The report raises the question of whether such use could act as a risk factor for oral mucosal malignant melanoma, but a single case cannot establish that relationship. The same source notes that Melanotan II is unlicensed and that its sale is illegal in the United Kingdom [3].

Melanotan II and antidepressant-like effects in male rats under chronic unpredictable stress

In male rats exposed to a chronic unpredictable stress model, the ACTH(4-10) synthetic analogs Semax and Melanotan II were studied for antidepressant-like and antistress effects [4]. The rationale given is that stressful events and hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis play an important role in the pathogenesis of depression, and that current antidepressant therapy has substantial limitations [4]. This is animal-only evidence. Findings in a rat stress model do not translate directly to human depression, and the evidence block does not provide effect sizes or a full behavioural dataset.

Melanotan II and analytical identification in seized samples

A laboratory identification study examined submitted samples, including two vials with a pharmaceutical appearance, using HPLC-DAD, UHPLC-TOF-MS, and/or UPLC-MS-MS [5]. The work describes the unique characteristics observed during analysis of the powder contained in the vial, in a report on what is sometimes called 'Barbie drug' identification [5]. This is analytical chemistry rather than pharmacology: it speaks to how the compound can be detected and characterised in a sample, not to any biological effect. It is relevant to researchers because it shows that identity confirmation of research materials is a distinct analytical problem from receptor pharmacology.

Melanotan II and the melanocortin receptor tool-compound literature

A review of recommended tool compounds for the melanocortin receptor (MCR) G protein-coupled receptors describes the family as centrally and peripherally expressed Class A GPCRs with physiological roles including pigmentation, steroidogenesis, and energy homeostasis, and notes that some roles remain to be fully characterised [6]. There are five melanocortin receptor subtypes; apart from the melanocortin-2 receptor (MC2R), the family is discussed together in that review [6]. Melanotan II appears in this literature as a non-selective melanocortin receptor agonist, which is why its effects in any given tissue depend on which receptor subtypes that tissue expresses. This is a reference framework rather than a primary finding about Melanotan II itself.

Melanotan II and receptor selectivity across the melanocortin family

Because Melanotan II is described as acting primarily at melanocortin 1 receptors on melanocytes [1] while the melanocortin family includes five subtypes with distinct tissue distributions [6], the compound's profile in a given experiment depends on the receptor complement of the model used. The pigmentation endpoint in the human case report [1] is consistent with MC1R activation on melanocytes. The rat stress-model work [4] concerns central effects, which would implicate receptor subtypes expressed in the central nervous system rather than the melanocyte MC1R population. The evidence block does not provide binding affinities or subtype selectivity constants, so no quantitative selectivity table can be constructed from these sources.

Melanotan II and the gap between human reports and controlled data

The human evidence in this set consists of two case reports [1][3] and one registered trial record without posted results [2]. The case reports describe pigmentation findings in the oral mucosa [1] and a maxillary mass in a nasal-spray user [3]; neither can establish incidence, dose-response, or causation. The trial record [2] describes a randomized Phase 2 design in stable nonsegmental vitiligo but reports no outcomes in the evidence block. The animal evidence [4] is confined to male rats in a chronic unpredictable stress model. The analytical evidence [5] addresses sample identification. Taken together, the sources support statements about mechanism and about what has been observed, but they do not support statements about efficacy, safety margins, or typical effects in any population.

Melanotan II and regulatory status as reported in the sources

Two sources in this set address regulatory status directly. The case report on oral mucosal changes states that Melanotan II remains unregulated despite its popularity, particularly through social media promotion, and that its use is associated with a range of potential adverse effects [1]. The nasal-spray case report states that Melanotan II is unlicensed and that its sale is illegal in the United Kingdom [3]. These are the only regulatory statements available in the evidence block; no other jurisdiction is characterised here.

If you are reading this for personal health reasons

This material is sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician. Nothing on this page is medical advice or a recommendation for human use.

Sources

WhatsApp